Medicenna Therapeutics Corp. announced that a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy for the treatment of patients with recurrent glioblastoma (rGBM), will be presented by Dr. Steven Brem, M.D. (Medical Director, Centre for Precision Surgery, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania) at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. "Bizaxofusp represents an exciting new approach by demonstrating a dose-dependent effect on the receptor of IL-4, an immuno-suppressive cytokine.

Further, use of bizaxofusp as a single agent or in combination could "flip the switch" on glioblastoma to convert it from an immunologically "cold" (unresponsive) tumor to one that is responsive, using convection enhanced delivery to "take the fight to the tumor". Bizaxofusp (formerly known as MDNA55) is Medicenna's IL-4 Empowered Superkine that has been studied in 5 clinical trials in over 130 patients, including a Phase 2b trial in patients with recurrent gliob Lastoma (rGBM), the most common and uniformly fatal form of brain cancer. Results from the Phase 2b study, which were published in the journal Neuro-Oncology®?

(Sampson, et al. June 2023), demonstrated that bizaxofusp more than doubled the median survival in end-stage rGBM patients when compared to a well-matched external control arm. Medicenna has obtained agreement from the U.S. FDA on the study design for the registrational Phase 3 LIGHT??

(Localized Infusion for the treatment of recurrent Glioblastoma with High-dose bizaxofusp Therapy) trial and the Company is actively pursuing potential partnerships to conduct the LIGHT trial, and if approved, bizaxofusp's commercialization in key global markets. Bizaxofusp has been granted FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.